Ana Belén
Remírez Sanz de Acedo
Investigadora Colaboradora
![Foto de Ana Belén](/img/nophoto.png)
![Foto de Instituto de Salud Carlos III](/img/noimage_org.png)
Instituto de Salud Carlos III
Madrid, EspañaInstituto de Salud Carlos III -ko ikertzaileekin lankidetzan egindako argitalpenak (1)
2021
-
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3